从TRIPLETE研究再看左半RAS/BRAF野生型转移性结直肠癌一线治疗的强化策略OA

The phase Ⅲ TRIPLETE trial compared the triplet regimen modified FOLFOXIRI versus the doublet regimen mFOLFOX6,both combined with an anti-epidermal growth factor receptor(EGFR)antibody,as a first-line treatment for patients with rat sarcoma viral oncogene homolog(RAS)/B-Raf proto oncogene serine/threonine protein kinase(BRAF)wild-type metastatic colorectal cancer(mCRC).The results demonstrated a significant 7.8-month improvement in overall survival(OS)for patients receiving the triplet regimen,providing high-level evidence of a survival benefit for combining triplet chemotherapy with anti-EGFR therapy.This article analyzes the potential reasons for the observed discordance between the OS benefit and objective response rate(ORR)results in the TRIPLETE study.Further-more,it discusses key implementation considerations and optimization strategies for combining anti-EGFR monoclonal antibodies with triplet chemotherapy regimens in clinical practice for advanced malignancies,with the aim of helping patients derive maximum survival benefit from this intensified approach.